Treatment options for brain metastases from melanoma

Expert Review of Anticancer Therapy

Volumn 5, Issue 5, 2005, Pages 809-820

  McWilliams, Rrobert R ^a   Rao, Ravi D ^b   Brown, Paul D ^b   Link, Michael J ^b   Buckner, Jan C ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

Brain metastasis; Melanoma; Treatment

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CORTICOSTEROID; DACARBAZINE; DOCETAXEL; FOTEMUSTINE; INTERLEUKIN 2; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TEMOZOLOMIDE; THALIDOMIDE; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

BEAM THERAPY; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CRANIOTOMY; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG PENETRATION; EVIDENCE BASED MEDICINE; HEMATOLOGIC DISEASE; HUMAN; MELANOMA; MINIMALLY INVASIVE SURGERY; MOTOR DYSFUNCTION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PROGNOSIS; QUALITY OF LIFE; RADIOSURGERY; REVIEW; SENSORY DYSFUNCTION; SEPSIS; STEREOTAXIC SURGERY; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; TREMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; MELANOMA; PALLIATIVE CARE; PROGNOSIS; RADIOSURGERY; SKIN NEOPLASMS;

EID: 27744491997     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.5.809     Document Type: Review

References (78)

1. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 43(7), 3427-3433 (1983).
2. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am. J. Surg. 135(6), 807-810 (1978).
3. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42(2), 660-668 (1978).
4. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J. Neurooncol. 1(4), 313-317 (1983).
5. Sze G, Shin J, Krol G, Johnson C, Liu D, Deck MD. Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT Radiology 168(1), 187-194 (1988).
6. Davis PC, Hudgins PA, Peterman SB, Hoffman JC Jr. Diagnosis of cerebral metastases: double-dose delayed CT vs. contrast-enhanced MR imaging. Am. J. Neuroradiol. 12(2), 293-300 (1991).
7. Taphoorn MJ, Heimans JJ, Kaiser MC, de Slegte RG, Crezee FC, Valk J. Imaging of brain metastases. Comparison of computerized tomography (CT) and magnetic resonance imaging (MRI). Neuroradiology 31(5), 391-395 (1989).
8. Einhorn LH, Burgess MA, Vallejos C et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 34(8), 1995-2004 (1974).
9. Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur. J. Cancer 14(4), 327-330 (1978).
10. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37(4), 745-751 (1997).
11. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94(8), 2265-2272 (2002).
12. Morris SL, Low SH, A'Hern RP et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br. J. Cancer 91(5), 829-833 (2004).
13. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis [see comment]. Mayo Clin. Proc. 79(12), 1489-1494 (2004).
14. Forsyth PA, Weaver S, Fulton D et al. Prophylactic anticonvulsants in patients with brain tumour [see comment]. Can. J. Neurol. Sci. 30(2), 106-112 (2003).
15. Glantz MJ, Cole BF, Friedberg MH et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46(4), 985-991 (1996).
16. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 31(6), 830-833 (1971).
17. Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer 45(4), 679-683 (1980).
18. Stridsklev IC, Hagen S, Klepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol. Oncol. 23(4), 231-235 (1984).
19. Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 53(11), 2550-2552 (1984).
20. Gottlieb JA, Frei E III, Luce JK. An evaluation of the management of patients with cerebral metastases from malignant melanoma. Cancer 29(3), 701-705 (1972).
21. Fell DA, Leavens ME, McBride CM. Surgical versus nonsurgical management of metastatic melanoma of the brain. Neurosurgery 7(3), 238-242 (1980).
22. Cooper JS, Carella R. Radiotherapy of intracerebral metastatic malignant melanoma. Radiology 134(3), 735-738 (1980).
23. Ellerhorst J, Strom E, Nardone E, McCutcheon I. Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. Int. J. Radiat. Oncol. Biol. Phys. 49(1), 93-97 (2001).
24. Hornsey S. The radiosensitivity of melanoma cells in culture. Br. J. Radiol. 45(530), 158 (1972).
25. Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol. Oncol. 25(1), 1-10 (1986).
26. Hornsey S. The radiation response of human malignant melanoma cells in vitro and in vivo. Cancer Res. 32(3), 650-651 (1972).
27. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int. J. Radiat. Oncol. Biol. Phys. 15(4), 859-864 (1988).
28. Ziegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 12(10), 1839-1842 (1986).
29. Vlock DR, Kirkwood JM, Leutzinger C, Kapp DS, Fischer JJ. High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. Cancer 49(11), 2289-2294 (1982).
30. Hagen NA, Cirrincione C, Thaler HT, DeAngelis LM. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 40(1), 158-160 (1990).
31. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 93(1), 9-18 (2000).
32. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88(1), 11-20 (1998).
33. Patchell BA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial [comment]. JAMA 280(17), 1485-1489 (1998).
34. Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J. Neurosurg. 96(3), 552-558 (2002).
35. Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J. Neurosurg. Sci. 44(4), 211-219 (2000).
36. Katz HR. The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int. J. Radiat. Oncol. Biol. Phys. 7(7), 897-906 (1981).
37. Bremer AM, West CR, Didolkar MS. An evaluation of the surgical management of melanoma of the brain. J. Surg. Oncol. 10(3), 211-219 (1978).
38. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494-500 (1990).
39. Noordijk EM, Vecht CJ, Haaxma-Reiche H et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age [see comment]. Int. J. Radiat. Oncol. Biol. Phys. 29(4), 711-717 (1994).
40. Wornom IL III, Smith JW, Soong SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann. Surg. 204(2), 181-185 (1986).
41. Somaza S, Kondziolka D, Lunsford LD, Kirkwood JM, Flickinger JC. Stereotactic radiosurgery for cerebral metastatic melanoma. J. Neurosurg. 79(5), 661-666 (1993).
42. Seung SK, Shu HK, McDermott MW, Sneed PK, Larson DA. Stereotactic radiosurgery for malignant melanoma to the brain. Surg. Clin. North Am. 76(6), 1399-1411 (1996).
43. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL. Stereotactic radiosurgery for patients with 'radioresistant' brain metastases. Neurosurgery 51(3), 656-667 (2002).
44. Selek U, Chang EL, Hassenbusch SJ III et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 1097-1106 (2004).
45. Radbill AE, Fiveash JF, Falkenberg ET et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 101(4), 825-833 (2004).
46. Mingione V, Oliveira M, Prasad D, Steiner M, Steiner L. Gamma surgery for melanoma metastases in the brain. J. Neurosurg. 96(3), 544-551 (2002).
47. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int. J. Radiat. Oncol. Biol. Phys. 42(3), 581-589 (1998).
48. Lavine SD, Petrovich Z, Cohen-Gadol AA et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 44(1), 59-66 (1999).
49. Grob JJ, Regis J, Laurans R et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur. J. Cancer 34(8), 1187-1192 (1998).
50. Seung SK, Sneed PK, McDermott MW et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J. Sci. Am. 4(2), 103-109 (1998).
51. Gieger M, Wu JK, Ling MN, Wazer D, Tsai JS, Engler MJ. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat. Ontol. Investig. 5(2), 72-80 (1997).
52. Yu C, Chen JC, Apuzzo ML et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1277-1287 (2002).
53. Mañon RR ONA, Mehta M, Knisely J et al. Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: an Eastern Co-operative Oncology Group Study (E6397). Proc. Am. Soc. Clin. Oncol. (2004).
54. Aoyama H SH, Nakagawa K, Tago M. Interim report of the JROSG99-1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1-4 brain metastases. Proc. Am. Soc. Clin. Oncol. (2004).
55. Regine WF, Huhn JL, Patchell RA et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications [see comment] [erratum appears in Int. J. Radiat. Oncol. Biol. Phys. 2002 53(1), 259]. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 333-338 (2002).
56. Pavlick AC. Chemotherapy approaches to melanoma. Dermatol. Clin. 20(4), 709-712 (2002).
57. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85(7), 1599-1605 (1999).
58. Beretta G, Bonadonna G, Cascinelli N, Morabito A, Veronesi U. Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international co-operative study. Cancer Treat. Rep. 60(1), 33-40 (1976).
59. Boaziz C, Breau JL, Morere JF, Israel L. Metastases cerebrales des melanomes malins. Bull. Cancer 78(4), 347-353 (1991).
60. Kleeberg UR, Engel E, Israels P et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre Phase II trial of the EORTC-Melanoma Co-operative Group (MCG). Melanoma Res. 5(3), 195-200 (1995).
61. Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66(9), 1873-1878 (1990).
62. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med. 345(8), 621-622 (2001).
63. Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18(1), 158-166 (2000).
64. Bleehen NM, Newlands ES, Lee SM et al. Cancer Res.earch Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 13(4), 910-913 (1995).
65. Bafaloukos D, Tsoutsos D, Fountzilas G et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res. 14(4), 289-294 (2004).
66. Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a Phase II study. J. Clin. Oncol. 22(11), 2101-2107 (2004).
67. Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 21(17), 3351-3356 (2003).
68. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2(10), 634-635 (2001).
69. Hwu WJKS, Lis E, Menell JH et al. Phase II study of temozolomide (TMZ) plus thalidomide in patients with brain metastasis from malignant melanoma. Proc. Am. Soc. Clin. Oncol. (2003).
70. Mornex F, Thomas L, Mohr P et al. Essai de Phase III randomise comparant la fotemustine seule ou associee a une irradiation encephalique dans les metastases cerebrales de melanome. Cancer Radiother. 7(1), 1-8 (2003).
71. Dardoufas CMA, Skarleas C, Kouloulias V et al. Concomitant temozolomide (TMZ) and radiotherapy (RT) followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumours. Proc. Am. Soc. Clin. Oncol. (2001).
72. Margolin K, Atkins B, Thompson A et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a Phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 128(4), 214-218 (2002).
73. Atkins MBSJ, Agarwala S, Logan T et al. A Cytokine Working Group Phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. Proc. Am. Soc. Clin. Oncol. (2005).
74. Guirguis LM, Yang JC, White DE et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J. Immunother. 25(1), 82-87 (2002).
75. Spitler LE, Wong P, Sagebiel R. Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis. Archives of Dermatology 114(10), 1501-1504 (1978).
76. Savas B, Arslan G, Gelen T, Karpuzoglu G, Ozkaynak C. Multi-drug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Res. 19(5C), 4413-4420 (1999).
77. Boasberg PD, O'Day SJ, Knistedja TS et al. Biochemotherapy for metastatic melanoma with limited central nervous system involvement. Oncology 64(4), 328-335 (2003).
78. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J. Clin. Oncol. 12(3), 627-642 (1994).